aibioMPH Medicure Inc.
Medicure (MPH) news
Medicure Inc. is a public biotech or pharmaceutical company listed on TSXV under the ticker MPH, recorded under Canada. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest Medicure news
We have not published a story on Medicure yet. When there is news, it will appear here.
What Medicure does
Medicure Inc. has its registered and head office in Winnipeg, Manitoba, Canada. Its first commercial product, AGGRASTAT tirofiban hydrochloride injection, is sold in the United States, and the company acquired U.S. rights to it in August 2006. In February 2008 its pivotal Phase III MEND-CABG II trials with MC-1 did not meet the primary endpoint, and the company then restructured and reduced headcount. In 2014 it acquired a minority interest in Apicore, a process research and development and active pharmaceutical ingredients manufacturing service provider, and it later acquired a controlling interest. It sold its interests in Apicore in 2017. In December 2017 the company announced an exclusive license from Zydus for ZYPITAMAG, pitavastatin magnesium, a cardiovascular drug used for primary hyperlipidemia or mixed dyslipidemia, in the United States and its territories. The company has also financed its operations through debt, including a term loan from Crown Capital Fund IV LP and a loan under the Manitoba Industrial Opportunities Program.
| Product or program | What it is | Stage |
|---|---|---|
| AGGRASTAT (tirofiban hydrochloride) | Injection, the company's first commercial product, with U.S. rights acquired in 2006 | commercial product |
| ZYPITAMAG (pitavastatin magnesium) | Cardiovascular drug for primary hyperlipidemia or mixed dyslipidemia, licensed from Zydus for the US | |
| MC-1 | Candidate tested in the MEND-CABG II pivotal trials | Phase III; did not meet primary endpoint |
Medicure annual financials
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | C$21.9 million | C$21.7 million |
| Research and development | C$3.1 million | C$2.4 million |
| Net income (loss) | -C$1.0 million | -C$922,000 |
| Cash from operations | C$1.4 million | C$2.1 million |
| Cash and equivalents | C$7.2 million | C$6.4 million |
Questions about Medicure
What is the ticker symbol of Medicure?
Medicure Inc. trades under the ticker MPH on TSXV.
Where is Medicure listed?
Medicure Inc. is listed on TSXV. Our directory also records these other listings: GETTEX:NGQ1; LS:A1J7TZ; NEO:MPH; OTC:MCUJF.
What is the SEC CIK of Medicure?
The SEC Central Index Key (CIK) for Medicure Inc. is 1133519. Its filings are on SEC EDGAR.
How many shares does Medicure have outstanding?
10,436,313 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-24.
Which country or territory is Medicure listed under?
Our directory records Medicure Inc. under Canada.
What does Medicure do?
Our directory classifies Medicure Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Medicure?
The ISIN recorded for Medicure Inc. is CA58469E4085.
Does aibio.space cover Medicure?
aibio.space lists Medicure Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Medicure incorporated?
SEC records list its state or country of incorporation as A2.
What does Medicure develop?
Medicure Inc. has its registered and head office in Winnipeg, Manitoba, Canada. Its first commercial product, AGGRASTAT tirofiban hydrochloride injection, is sold in the United States, and the company acquired U.S. rights to it in August 2006.
What is AGGRASTAT (tirofiban hydrochloride) from Medicure?
AGGRASTAT (tirofiban hydrochloride): Injection, the company's first commercial product, with U.S. rights acquired in 2006 Stage: commercial product.
What is ZYPITAMAG (pitavastatin magnesium) from Medicure?
ZYPITAMAG (pitavastatin magnesium): Cardiovascular drug for primary hyperlipidemia or mixed dyslipidemia, licensed from Zydus for the US
Is Medicure a smaller reporting company?
SEC records list Medicure Inc.'s filer category as: Non-accelerated filer.
Where is Medicure headquartered?
SEC records list its business address as SUITE 2, WINNIPEG, R2C 0A1.
When does Medicure's fiscal year end?
Medicure Inc.'s fiscal year ends on December 31, per SEC records.
Investor discussion: Medicure
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Legal
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 20-F. Source
Stock chart
SEC filings and registration
- SEC name
- Medicure Inc
- CIK
- 1133519
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- MCUJF (OTC)
- State or country of incorporation
- A2
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer
- Business address
- SUITE 2, WINNIPEG, R2C 0A1
- Phone
- 204-487-7412
- Shares outstanding
- 10,436,313 as of 2025-12-31 (20-F filed 2026-04-24)
Recent filings
Listing details
- Company
- Medicure Inc.
- Ticker
- MPH
- Listing
- TSXV
- Country or territory
- Canada
- Business scope
- Pharmaceuticals: Major
- ISIN
- CA58469E4085
- Other listed symbols
- GETTEX:NGQ1; LS:A1J7TZ; NEO:MPH; OTC:MCUJF
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction